Medication for improving quality of life in women with abdominal pain

Allopurinol for improving the quality of life in endometriosis: a randomized controlled trial - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059190

Enrollment

Registered

2023-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Allopurinol: Tab Dienogest 2 mg once daily plus Tab Allopurinol 300mg once daily for three months Control Intervention1: Placebo: Tab dienogest 2 mg once daily plus multivitamin tablet

Eligibility

Inclusion criteria

Inclusion criteria: Patients with subjective symptoms. Patients willing to comply with the treatment. Patients not received any hormonal treatment in 2 cycles prior.

Exclusion criteria

Exclusion criteria: Patients with known allergy or hypersensitivity to one or both of the drugs. Patients who are pregnant or lactating. Patients taking part in any other clinical trials. Patients with active sexually transmitted infections. Patients with any coexisting chronic disease Patients with routine consumption of analgesics for reasons other than endometriosis. Patients with undiagnosed abnormal genital bleeding.

Design outcomes

Primary

Measure	Time frame
VAS scoreTimepoint: 0 and 3 months	—

Secondary

Measure	Time frame
Biberoglu and Behrman score (B&B) WHO Quality of Life Questionnaire (WHOQOL-BREF) Patient Health Questionnaire (PHQ-9) Female Sexual Function Inventory (FSFI) Timepoint: 0 and 3 months	—

Countries

India

Contacts

Public ContactDr Srirameena V

All India Institute of Medical Sciences Bhubaneswar

obgyn_sweta@aiimsbhubaneswar.edu.in9438884131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026